MedTrace Logo

Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)

NCT02724618 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2017-10-12

No results posted yet for this study

Summary

There is a growing body of evidence exploring the role of curcumin as a radioprotector against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy.

Conditions

Interventions

DRUG

Curcumin

120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy

RADIATION

RT

EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT

DRUG

Placebo

Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy

Sponsors & Collaborators

  • Behnam Daheshpour Charity Organization, Tehran, Iran

    collaborator UNKNOWN

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Abolfazl Razzaghdoust · Shahid Beheshti University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-04-15
Completion
2022-04-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02724618 on ClinicalTrials.gov